Pharma BD Deal Intelligence
Cheap optionality on an oral dual agonist, with the clinical risk still entirely ahead
Full analysis, sources & comparables →Novo Nordisk obtained exclusive rights to develop, manufacture and commercialise HRS-1596, a once-weekly oral GLP-1/GIP dual receptor agonist, in all territories outside mainland China, Hong Kong, Macao and Taiwan. Hengrui receives a USD 300 million upfront payment plus milestones taking total potential consideration to up to USD 2.6 billion, together with royalties on net sales. HRS-1596 is Phase 1-ready; Hengrui has received China approval to initiate Phase I trials in weight management and type 2 diabetes. Closing is expected in the fourth quarter of 2026.
Cheap optionality on an oral dual agonist, with the clinical risk still entirely ahead
Assessment window: 5yr post-close.
Note: this deal's 5-year assessment window closes ~2031; the outcome grade above is a projected assessment, not yet finalized.
Obesity is a chronic metabolic disease measured by BMI >=30 and is the largest commercial market in metabolic medicine. CDC/NCHS NHANES measured-height-and-weight data for August 2021-August 2023 put age-adjusted adult obesity prevalence at 40.3%, with severe obesity at 9.7% and a further 31.7% of adults overweight. Prevalence peaks in adults aged 40-59 (46.4%).
Oral incretin therapy is the next competitive front in obesity after injectable GLP-1s. HRS-1596 is a once-weekly oral GLP-1/GIP dual receptor agonist, giving Novo Nordisk an ex-China oral dual-agonist option alongside its existing incretin franchise.
Type 2 diabetes is a progressive metabolic disease of insulin resistance and relative insulin deficiency. Per the CDC National Diabetes Statistics Report, an estimated 40.1 million people in the United States (12.0%) had diagnosed or undiagnosed diabetes in 2023, and type 2 diabetes represents approximately 90-95% of diagnosed adult cases.
Hengrui has received China approval to initiate Phase I studies of HRS-1596 in both weight management and type 2 diabetes, so the in-licensed asset carries a dual metabolic label opportunity rather than an obesity-only one.
Novo Nordisk obtained exclusive rights to develop, manufacture and commercialise HRS-1596, a once-weekly oral GLP-1/GIP dual receptor agonist, in all territories outside mainland China, Hong Kong, Macao and Taiwan. Hengrui receives USD 300 million upfront plus milestones to a total of up to USD 2.6 billion, together with royalties on net sales.
The companies stated that closing of the licence agreement is expected in the fourth quarter of 2026, subject to customary conditions.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Nordisk A/S / Jiangsu Hengrui Pharmaceuticals Co. Ltd. (this deal) | 2026 | $2.6B | 62 |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2019 | $3.3B | 88 |
| Novo Nordisk A/S / Vivtex Inc. | 2026 | $2.1B | 69 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2021 | $3.3B | 68 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 68 |
| Novo Nordisk A/S / Inversago Pharma | 2023 | $1.1B | 61 |
← Browse all deals · How we score deals
More: 2026 deals · Novo Nordisk A/S deals